logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Organ Rejection

    Medications for Organ Rejection

    FiltersReset Filters
    14 results

    • envarsus

      (Tacrolimus)
      Veloxis Pharmaceuticals, Inc
      Usage: ENVARSUS XR is indicated for the prophylaxis of organ rejection in de novo kidney transplant patients and those converting from tacrolimus immediate-release formulations, used in combination with other immunosuppressants.

    • mycophenolate mofetil

      (Mycophenolate Mofetil)
      Meitheal Pharmaceuticals Inc.
      Usage: Mycophenolate Mofetil is indicated for the prevention of organ rejection in adults and pediatric patients (3 months and older) undergoing allogenic kidney, heart, or liver transplants, in conjunction with other immunosuppressants.

    • mycophenolate mofetil

      (Mycophenolate mofetil)
      Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
      Usage: Mycophenolate mofetil (MMF) is indicated for the prevention of organ rejection in adult and pediatric recipients (aged 3 months and older) of allogeneic kidney, heart, or liver transplants, used in conjunction with other immunosuppressants.

    • mycophenolate mofetil

      (Mycophenolate mofetil)
      Strides Pharma Science Limited
      Usage: Mycophenolate mofetil (MMF) is indicated for preventing organ rejection in adult and pediatric patients aged 3 months and older who have received allogeneic kidney, heart, or liver transplants, used in combination with other immunosuppressants.

    • mycophenolic acid

      (mycophenilic acid)
      Archis Pharma LLC
      Usage: Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in kidney transplant patients, both adult and pediatric (5 years and older), in combination with cyclosporine and corticosteroids. Use interchangeably with mycophenolate mofetil is not recommended without physician supervision.

    • mycophenolic acid

      (MYCOPHENOLIC ACID)
      Ascend Laboratories, LLC
      Usage: Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in adults and pediatric patients (5 years and older) following kidney transplant, to be used in combination with cyclosporine and corticosteroids. Interchangeability with mycophenolate mofetil requires physician supervision due to absorption differences.

    • myfortic

      (mycophenolic acid)
      Novartis Pharmaceuticals Corporation
      Usage: Myfortic (mycophenolic acid) is indicated for the prophylaxis of organ rejection in adult and pediatric kidney transplant patients (5 years and older, at least 6 months post-transplant), to be used alongside cyclosporine and corticosteroids. Use caution as it should not be interchangeable with mycophenolate mofetil without physician supervision.

    • nulojix

      (BELATACEPT)
      E.R. Squibb & Sons, L.L.C.
      Usage: NULOJIX (belatacept) is indicated for the prevention of organ rejection in adult kidney transplant recipients, used in conjunction with basiliximab induction, mycophenolate mofetil, and corticosteroids. It is limited to EBV seropositive patients and is not approved for other transplanted organs.

    • prednisolone sodium phosphate

      (Prednisolone Sodium Phosphate)
      Edenbridge Pharmaceuticals LLC.
      Usage: Prednisolone Sodium Phosphate Oral Solution is indicated for various conditions including severe allergic reactions, dermatologic diseases, edematous states, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, acute exacerbations of multiple sclerosis, ophthalmic diseases, respiratory diseases, rheumatic disorders, and specific tuberculosis complications.

    • sandimmune

      (cyclosporine)
      Novartis Pharmaceuticals Corporation
      Usage: Sandimmune (cyclosporine) is indicated for preventing organ rejection in kidney, liver, and heart transplants, to be used with adrenal corticosteroids. It may also treat chronic rejection in patients previously on other immunosuppressants. Injection form is reserved for patients who cannot take oral formulations due to anaphylaxis risk.